MENU
+Compare
SNDX
Stock ticker: NASDAQ
AS OF
Sep 26 closing price
Price
$15.68
Change
+$0.65 (+4.32%)
Capitalization
1.35B

SNDX Syndax Pharmaceuticals Forecast, Technical & Fundamental Analysis

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications... Show more

Industry: #Biotechnology
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for SNDX with price predictions
Sep 26, 2025

Momentum Indicator for SNDX turns positive, indicating new upward trend

SNDX saw its Momentum Indicator move above the 0 level on September 26, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned positive. In of the 81 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 55 cases where SNDX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The 50-day moving average for SNDX moved above the 200-day moving average on September 15, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SNDX advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .

SNDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for SNDX moved out of overbought territory on September 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for SNDX turned negative on September 02, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SNDX entered a downward trend on September 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SNDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.584) is normal, around the industry mean (19.823). P/E Ratio (0.000) is within average values for comparable stocks, (53.778). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.098). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (17.331) is also within normal values, averaging (349.540).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

SNDX is expected to report earnings to fall 13.53% to -71 cents per share on November 11

Syndax Pharmaceuticals SNDX Stock Earnings Reports
Q3'25
Est.
$-0.72
Q2'25
Beat
by $0.18
Q1'25
Beat
by $0.26
Q4'24
Missed
by $0.26
Q3'24
Beat
by $0.09
The last earnings report on August 04 showed earnings per share of -82 cents, beating the estimate of -100 cents. With 2.92M shares outstanding, the current market capitalization sits at 1.35B.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals for novel cancer therapies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
35 Gatehouse Drive
Phone
+1 781 419-1400
Employees
184
Web
https://www.syndax.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FMCCX48.320.52
+1.09%
Fidelity Advisor Stock Selec Mid Cp I
FTHFX50.110.54
+1.09%
FullerThaler Behavioral Sm-Cp Eq R6
SSDZX36.040.30
+0.84%
DWS Small Cap Growth R6
IEDZX13.940.10
+0.72%
Voya Large Cap Value R6
HEIIX13.800.06
+0.44%
Hennessy Equity and Income Institutional

SNDX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with REPL. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
+4.32%
REPL - SNDX
50%
Loosely correlated
+1.98%
CGON - SNDX
50%
Loosely correlated
+2.91%
NUVL - SNDX
48%
Loosely correlated
+4.99%
NRIX - SNDX
47%
Loosely correlated
+7.20%
XENE - SNDX
46%
Loosely correlated
+4.00%
More